Sponsored Supplement

Challenges, Evidence, and Treatment Options for Anticoagulation of Obese and Morbidly Obese Patients with Nonvalvular Atrial Fibrillation (NVAF)

Sponsored by Janssen Pharmaceuticals, Inc.


In this supplement, Paul P. Dobesh, PharmD, examines NVAF in the obese and morbidly obese patient population with a focus on anticoagulant treatment options. Topics include:

  • Understanding the obesity risk in patients with NVAF
  • Challenges of anticoagulation with warfarin in patients with obesity
  • NVAF patients with obesity

Click here to access the supplement.

January 2020 cp-127604v1

Next Article: